Harnessing serotonergic and dopaminergic pathways for lymphoma therapy: Evidence and aspirations

Research output: Contribution to journalArticle

Colleges, School and Institutes


Growing evidence supports the notion that pharmaceutical targeting of the 5-hydroxytryptamine (5-HT) and dopamine (DA) systems offers the potential to treat human immune system disorders. This review describes this emerging area of research, which has the benefit of being supported by a relatively detailed understanding of these monoamine systems within other tissues of the body. Furthermore, the availability of a number of pharmaceutical agents originally developed to manipulate central monoamine function, offer many suitable drug candidates to test their therapeutic potential in the immune pathology arena.


Original languageEnglish
Pages (from-to)218-25
Number of pages8
JournalSeminars in Cancer Biology
Publication statusPublished - 1 Jun 2008


  • serotonin, dopamine, novel drug targets, lymphoma, drug reprofiling